Cat.No. : AAV00112Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 3 Storage: -80 ℃
| Cat. No. | AAV00112Z |
| Description | AAV serotype 3 particles contain no transgene under CMV promoter. |
| Serotype | AAV Serotype 3 |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
PCSK9 (proprotein convertase subtilisin/kexin type 9) plays an important role in lipoprotein metabolism by regulating LDL receptor homeostasis. Gain-of-function mutations in the human PCSK9 protein are associated with autosomal dominant hypercholesterolemia. Two research groups used an adeno-associated virus (AAV)-mediated gene transfer approach to investigate the effects of a well-characterized gain-of-function mutation in humans, D374Y, on atherosclerosis in mice. This approach resulted in a rapid increase in plasma cholesterol concentrations in C57BL/6 mice via a single injection of AAV containing the human PCSK9D374Y mutation or its mouse equivalent, the D377Y mutation. Thus, this single injection accelerated atherosclerosis in mice. In this study, the researchers demonstrated that the AAV-delivered mouse PCSK9D377Y mutation rapidly enhanced AngII-induced AAA in male C57BL/6 mice.
To evaluate the expression efficiency and stability of the AAV vectors, the researchers measured plasma PCSK9 concentrations at week 0 (before AAV injection) and at 2 and 6 weeks after AAV injection. Plasma PCSK9 concentrations were lower and remained unchanged in C57BL/6 mice that received an AAV vector containing a null insert (Figure 1A). In C57BL/6 mice infected with an AAV vector expressing the PCSK9D377Y mutation, plasma PCSK9 concentrations were significantly elevated 2 weeks after injection and remained high during 6 weeks of Western diet feeding. There was no difference in plasma PCSK9 concentrations between mice infected with 10×1010 and 30×1010 genome copies (Figure 1A). Consistent with the increase in plasma PCSK9 concentrations, plasma cholesterol concentrations increased significantly and consistently during 6 weeks of Western diet feeding (Figure 1B). All three dose groups of PCSK9D377Y.AAV increased atherosclerotic lesions (Figure 1C), while only the medium and high doses of PCSK9D377Y mutant groups resulted in an increase in AngII-induced AAA (Figure 1D).
Figure 1. Dose-response curve of AAV vector infection with PCSK9 gain-of-function mutation in C57BL/6 mice. (Lu H, et al., 2016)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
I’ve been using the AAV3-Null product for several months now, and I am thoroughly impressed by its consistency and effectiveness.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
